Key result
Current evidence suggests a potential pathological role for agonistic autoantibodies against the angiotensin II type 1 receptor in primary aldosteronism, though studies report highly contrasting results.
Why the study?
Any functional role of agonistic autoantibodies against the angiotensin II type 1 receptor in either of the two main subtypes of primary aldosteronism required clarification.
Current evidence on the role of AT1R autoantibodies in primary aldosteronism is highly variable and assay-dependent, warranting further investigation into their functional relevance.
Does not support AT1R autoantibody testing in primary aldosteronism; leaves open their functional role pending standardized assays.
Primary aldosteronism (PA) is the most common form of endocrine hypertension. Agonistic autoantibodies against the angiotensin II type 1 receptor (AT1R-Abs) have been described in transplantation medicine and women with pre-eclampsia and more recently in patients with PA. Any functional role of AT1R-Abs in either of the two main subtypes of PA (aldosterone-producing adenoma or bilateral adrenal hyperplasia) requires clarification. In this review, we discuss the studies performed to date on AT1R-Abs in PA.
No takes yet. Share an insight, caveat, or question.
Meyer et al. (2020) conducted a review in Primary aldosteronism. Angiotensin II type 1 receptor autoantibodies (AT1R-Abs) was evaluated. Current evidence suggests a potential pathological role for agonistic autoantibodies against the angiotensin II type 1 receptor in primary aldosteronism, though studies report highly contrasting results.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: